CRDL vs. TLRY, VBV, CUS, AIM, IPA, FRX, APM, GXE, ITH, and GPH
Should you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include Tilray Brands (TLRY), VBI Vaccines (VBV), Chemtrade Electrochem Inc, (CUS), Aimia (AIM), ImmunoPrecise Antibodies (IPA), Fennec Pharmaceuticals (FRX), Andean Precious Metals (APM), Gear Energy (GXE), International Tower Hill Mines (ITH), and Graphite One (GPH). These companies are all part of the "pharmaceutical products" industry.
Cardiol Therapeutics vs.
Tilray Brands (TSE:TLRY) and Cardiol Therapeutics (TSE:CRDL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, community ranking, earnings and risk.
In the previous week, Tilray Brands had 6 more articles in the media than Cardiol Therapeutics. MarketBeat recorded 7 mentions for Tilray Brands and 1 mentions for Cardiol Therapeutics. Tilray Brands' average media sentiment score of 0.37 beat Cardiol Therapeutics' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the media.
Cardiol Therapeutics has lower revenue, but higher earnings than Tilray Brands. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.
Tilray Brands has a beta of 2.19, suggesting that its share price is 119% more volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.
Cardiol Therapeutics has a net margin of 0.00% compared to Tilray Brands' net margin of -30.02%. Tilray Brands' return on equity of -7.24% beat Cardiol Therapeutics' return on equity.
11.2% of Tilray Brands shares are held by institutional investors. Comparatively, 11.4% of Cardiol Therapeutics shares are held by institutional investors. 0.7% of Tilray Brands shares are held by company insiders. Comparatively, 4.6% of Cardiol Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Cardiol Therapeutics received 9 more outperform votes than Tilray Brands when rated by MarketBeat users. Likewise, 69.23% of users gave Cardiol Therapeutics an outperform vote while only 0.00% of users gave Tilray Brands an outperform vote.
Summary
Tilray Brands and Cardiol Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Cardiol Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiol Therapeutics Competitors List
Related Companies and Tools
This page (TSE:CRDL) was last updated on 4/18/2025 by MarketBeat.com Staff
Buy CRDL Stock Free CRDL Stock Alerts